Vir Biotechnology’s ECLIPSE-1 data arrive Sunday. Can monthly therapy challenge Hepcludex?
Vir Biotechnology will reveal ECLIPSE-1 hepatitis delta results on November 8. Examine clinical endpoints, Hepcludex competition and regulatory stakes.
Pharma & Biotech
Pharma & Biotech
Why FDA approval for Hepcludex changes the treatment landscape for hepatitis delta virus
Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.
Pharma & Biotech
How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization
FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.